Oregon tested whether menstrual cycle phase changes middle-distance running performance. What actually mattered was the capacity to consume oxygen.
9 highly trained women. Two time-to-exhaustion trials timed to low and high hormone phases. Blood, muscle, and metabolic profiling at every step.
Wilkins, Richardson & Schoeberlein — Oregon Performance Research Lab, University of Oregon
Kirby — Nike Sport Research Lab
Estrogen and progesterone fluctuate dramatically across the menstrual cycle, affecting cardiovascular, respiratory, metabolic, and neuromuscular systems. Popular strategies claim training and racing should be timed to cycle phase.
But a 2020 meta-analysis found only a "trivial detrimental effect" of the early follicular phase on performance — and half the studies didn't even verify hormone levels with bloodwork.
Oregon's approach: verify hormones, test performance, and measure everything in between — in athletes actually running at 4-minute mile pace.
| Measure | Group Mean |
|---|---|
| VO₂max | 58.6 ± 6.5 mL/kg/min |
| TTE speed | 17.1 ± 1.4 kph |
| Avg pace | 5:42 ± 0:30 per mile |
| Avg TTE | 223.8 ± 39.8 sec |
These are highly trained middle-distance runners — averaging sub-6 minute miles, running to exhaustion in about 3:44. Four with natural cycles, four with IUDs, one on combination birth control.
Continuous VO₂ kinetics, muscle oxygenation (NIRS), heart rate, and blood lactate were measured throughout every trial. Hormone status was verified by blood, not assumed from calendar.
No statistically significant difference in time to exhaustion between low and high hormone profile days
But the group average hides a more interesting story. Here is every participant's change in TTE from low to high hormone day:
Five participants ran shorter on the high hormone day, two ran longer, and one was essentially unchanged (~1 sec). There was no correlation between progesterone or estradiol concentration and TTE performance (r = 0.14 and r = –0.14, respectively).
So if the hormones themselves don't explain the variation — what does?
When Oregon looked at which physiological characteristics actually predicted how fast their athletes ran, the results were overwhelming:
The message is clear: your physiology — not your cycle phase — determines how fast you run. VO₂max and lactate turnpoint explain over 85% of the variance in performance.
When the Oregon team explored what actually explained the individual differences in performance between low and high hormone days, two critical links emerged — muscle oxidative capacity and hemoglobin mass:
Hb mass per kg body mass vs. change in TTE
P = 0.02
Red blood cell volume (RBCV) vs. change in TTE
P = 0.049
Athletes who maintained their hemoglobin mass and red blood cell volume between trial days maintained their running performance. The relationship was statistically significant and robust.
Both ΔPV (P = 0.003) and ΔBV (P = 0.02) were negatively correlated with ΔTTE — increased plasma volume diluted oxygen-carrying capacity and hurt performance.
Slower VO₂ onset kinetics (r = –0.63, P = 0.09) on the high hormone day were associated with shorter TTE — suggesting oxygen delivery speed also fluctuates with hormone profile.
There was a modest relationship between progesterone and blood volume (r = 0.65, P = 0.12), pointing to a possible mechanism: high progesterone may expand plasma volume, diluting Hb concentration and reducing oxygen delivery — which is what actually impacts performance.
Menstrual cycle phase alone doesn't predict performance in trained women. The popular advice to periodize training around cycle phase isn't supported by this data. What matters is the capacity to consume oxygen — muscle oxidative capacity and hemoglobin mass.
The individual variability is the finding. Group averages mask real physiological responses. Future work should track muscle oxidative capacity and Hb mass alongside hormone profiles to isolate the mechanism — not just the phase.
If the 4-minute mile hinges on oxygen delivery — and the Exeter model says it does — then muscle oxidative capacity and hemoglobin mass are more relevant than estrogen or progesterone directly. Protecting the capacity to consume oxygen is the priority.
The cycle doesn't predict performance. Oxygen capacity does.
Oregon's data shows that fluctuating female sex hormones don't have a direct, measurable impact on middle-distance running performance in trained athletes. But the capacity to consume oxygen — muscle oxidative capacity and hemoglobin mass — is powerfully linked to individual performance differences. These two critical links define what actually matters for performance across the cycle.
This study is one chapter in a multi-institution scientific expedition exploring the limits of the women's 4-minute mile.
See the full series →